HOME >> BIOLOGY >> NEWS
Dendreon identifies novel approach to improve immunization efficiency

Seattle, WA (Nov. 28, 2000) Researchers at Dendreon Corporation have reported a novel method for generating an enhanced immune response with potentially important implications for improving the efficiency of therapeutic cancer vaccines. The data, published in the December issue of Nature Biotechnology, highlights a method for modifying targets on cancer cells called antigens to facilitate activation of cytotoxic T cells a key component of the immune system responsible for destroying cancerous cells.

Cancer vaccines are designed to jumpstart the immune systems natural disease-fighting ability. Cytotoxic T-cells in particular have been shown to be directly responsible for killing cancerous cells. Cytotoxic T-cells are educated to detect antigens on cancer cells by dendritic cells immune system watchdogs that internalize and process antigens prior to bringing them to the attention of T-cells.

In their study, Dendreon researchers found that a cytotoxic T-cell response could be greatly enhanced by engineering an antigen in a way that optimizes its uptake and processing by dendritic cells. Their approach involves the addition of a peptidic sequence to a modified, soluble protein antigen. Researchers analyzed the T-cell response elicited by the modified antigen in mouse models and found that mice immunized with the modified antigen generated significant cytotoxic T-cell activity while mice that received unmodified antigen showed no T-cell response.

"Our research provides strong evidence that a robust, enhanced T-cell response can be elicited through this type of antigen engineering. These findings also complement our Antigen Delivery Cassette technology," said Dr. Reiner Laus, lead author of the publication and vice president of immunology at Dendreon Corporation. "This is a novel approach with important implications for the immunotherapy of cancer."

The methodology described in the report is applicable to the development of a variety of vacci
'"/>

Contact: Page Sargisson
p.sargisson@noonanrusso.com
415-677-4455 x 229
Noonan/Russo Communications
27-Nov-2000


Page: 1 2

Related biology news :

1. Long-term data on Dendreons Mylovenge vaccine presented at American Society of Hematology
2. Chemical genetics identifies SARS inhibitors
3. U of T study identifies possible stem cells in pancreas
4. New view of leukemia cells identifies best treatment options, Stanford researchers say
5. Study identifies genetics of fat metabolism, red wine link
6. Gene expression ratio identifies risk of recurrence in breast cancer patients receiving tamoxifen
7. Study identifies which patients can benefit from targeted lung cancer drug and why
8. Researcher identifies Irish potato famine pathogen
9. U Iowa study identifies damaging mechanism in transplants and heart attacks
10. Computer method identifies potentially active enzymes
11. New study identifies inhibitor of anthrax toxin

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/1/2020)... (PRWEB) , ... April 30, 2020 , ... ... emerging infectious diseases, announced today that it had been awarded a contract from ... the Assistant Secretary for Preparedness and Response at the U.S. Department of Health ...
(Date:4/28/2020)... ... April 27, 2020 , ... Ofee.com, ... started by three teenagers with an idea to help millions of people during ... time of great need and suffering, an outlet has been created for people ...
(Date:4/22/2020)... ... April 21, 2020 , ... ... patent leveraged venture capital firm that provides patent development support for early stage ... and treat illnesses such as ovarian cancer and precancerous pancreatic lesions with simple, ...
Breaking Biology News(10 mins):
(Date:5/14/2020)... ... May 12, 2020 , ... ... translational research, is bringing together thousands of industry leaders, clinicians, research scientists, medical ... two plenary speakers, Carl June, MD, Director of the Center for Cellular Immunotherapies ...
(Date:5/9/2020)... ... ... Worldwide Business with kathy ireland® will be LIVE streaming ... and Wednesday, May 13, 2020 at 8:00pm ET / PT – prime time ... Techolution and Bravado Pharmaceuticals . , As leaders in their ...
(Date:5/5/2020)... Fla. (PRWEB) , ... May 05, 2020 , ... ... and solutions company, announced today the launch of its iGlucose® LTE ... new iGlucose solution utilizes LTE Cat-M1 technology, the industry’s newest and broadest cellular ...
(Date:4/23/2020)... ... 22, 2020 , ... Across the country, there is an ... Virginia has only been receiving 50% to 7.7% of the personal protective equipment ... Northam told the Virginia Mercury, “While we appreciate what we’ve received from the ...
Breaking Biology Technology:
Cached News: